Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Lepodisiran sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Lepodisiran sodium is a siRNA targeting Lp(a), at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.
Latest Hotspot
8 min read
Ravulizumab-CWVZ Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ravulizumab-CWVZ is a Monoclonal antibody targeting C5, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Pemvidutide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Pemvidutide is a Synthetic peptide targeting GCGR x GLP-1R, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
8 min read
DNMT3L 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for DNMT3L, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Pegozafermin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Pegozafermin is a Growth factors targeting FGF21R, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Eplontersen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Eplontersen is a ASO targeting TTR, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Olpasiran Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Olpasiran is a siRNA targeting Lp(a), at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Zilebesiran Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Zilebesiran is a siRNA targeting AGT, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Vutrisiran Sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Vutrisiran Sodium is a siRNA targeting TTR, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
8 min read
DDC 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for DDC, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Lanifibranor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Lanifibranor is a Small molecule drug targeting PPARα x PPARγ x PPARδ, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO.
Latest Hotspot
8 min read
Plozasiran Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Plozasiran is a siRNA targeting APOC3, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.